Company
Every investor coverage indicates participated in a round Baker Heart & Diabetes Institute raised.
Companies Baker Heart & Diabetes Institute acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Baker Heart & Diabetes Institute. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The federal MRFF has granted $50 million to the Artificial Heart Frontiers Program, a Monash-led consortium including BiVACOR, to advance a total artificial heart; the team earlier received $1 million in 2021.
Also @AuManufacturing
Profile of Sydney genomics startup 23Strands, covering its university and research collaborations, a $1 million grant, an NHMRC-backed project, and its 2020 UNSW Health10X accelerator background.
A consortium led by Monash University and BiVACOR won a $1 million Medical Research Future Fund grant to commercialise an Australian total artificial heart; BiVACOR had earlier closed a US$19 million Series B.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily